Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

University Health Network, Toronto

Status: Enrolling

Conditions: Solid Tumor; Breast Cancer; Melanoma; Lung Cancer; Pancreas Cancer; Leukemia; Ovary Cancer; Kidney Cancer; Lymphoma; Head and Neck Cancer; Prostate Cancer; Colorectal Cancer

Study type: Observational

Funder types: Other; NETWORK

Identifiers

NCT05403177

MOHCCN-O

Details and patient eligibility

About

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

Full description

The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy

2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:

   1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)
   2. Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization

3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.

4. Participating patients must agree to share their anonymized clinical and genomic data

Exclusion criteria

None.

Trial design

500 participants in 1 patient group

MOHCCN-O

Description:

Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and/or peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data.